Yahoo Search Búsqueda en la Web

Resultado de búsqueda

  1. 30 de abr. de 2024 · Latest News. April 30, 2024. Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum. April 26, 2024.

  2. 30 de abr. de 2024 · INDIANAPOLIS , March 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema.

  3. 30 de abr. de 2024 · Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum. Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea ...

  4. Hace 5 días · Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

    • c. 39,000 (2022)
    • US$28.54 billion (2022)
  5. 30 de abr. de 2024 · El laboratorio estadounidense Eli Lilly obtuvo unos beneficios netos de 2.243 millones de dólares (2.100 millones de euros) en el primer trimestre de 2023, un 40% más respecto a los 1.345 ...

  6. Hace 5 días · The U.S. Food and Drug Administration (FDA) will convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) on Monday, June 10, 2024, to discuss donanemab, which Eli Lilly and Company (NYSE: LLY) has submitted for the treatment of early symptomatic Alzheimer’s disease.

  7. 30 de abr. de 2024 · INDIANAPOLIS, April 30, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024. "Lilly's first quarter performance reflects ...

  1. Otras búsquedas realizadas